First Dual Monitoring Approval in the U.S.

The U.S. Food and Drug Administration (FDA) granted De Novo marketing authorization on August 25, 2026, for Abbott Diabetes Care, a division of Abbott Laboratories (ABT), for its Libre Duo 10 Day continuous glucose and ketone monitoring system. The device measures glucose and ketones in interstitial fluid every minute for 10 days and transmits readings and trend data to a smartphone. As the first continuous ketone monitor in the U.S. and the first globally to measure two analytes simultaneously using a single sensor, it differentiates itself from existing continuous glucose monitors (CGMs) in the approval and commercialization stages. The FDA established regulatory benchmarks for future products through the De Novo pathway and special controls for performance testing and labeling.

Clinical Evidence and Patient Safety

The approval is based on accuracy and performance data from six clinical trials involving over 600 participants aged two years and older. The sensor tracked clinically significant ketone differences and identified ketone elevations before diabetic ketoacidosis (DKA) occurred. Unlike pharmaceuticals that follow Phase 1–3 clinical trial systems, this medical device received Breakthrough Device designation and entered the De Novo authorization and commercialization process. Target analytes are glucose and ketones, providing trend information for insulin users and patients on SGLT2 inhibitors, where ketones may rise independently of glucose levels. However, alarms are not diagnostic and are designed to be interpreted alongside blood readings, symptoms, and medical guidance, which is a key factor in real-world clinical adoption.

Regulatory Expansion and Competitive Landscape

Abbott secured CE Mark for the 15-day Libre Duo for adults and the 10-day Libre Duo for those aged two years and older in Europe on May 27, 2026, followed by U.S. regulatory approval on August 25. The current standard involves blood ketone meters, urine test strips, and CGMs such as Dexcom (DXCM) G7 and Medtronic (MDT) Guardian 4 and Simplera Sync, but these CGMs do not measure ketones. Therefore, Abbott’s competitive advantage is formed not by CGM accuracy alone, but by early DKA alerts and integration into automated insulin delivery (AID) ecosystems. An exclusive collaboration with MiniMed (MMED) for smart dosing system integration serves as a distribution and conversion mechanism linking sensor approvals to pump platform market share.

Market Potential and Investment Implications

Grand View Research forecasts the global CGM device market to reach USD 15.5B in 2026 and USD 41.4B in 2033, with a compound annual growth rate of 15.1%. Abbott Diabetes Care revenue in Q2 2026 was USD 2.188B, a 10.5% increase year-over-year, with CGM revenue growth at 11.0% according to the report. Libre Duo targets approximately 2.1 million type 1 diabetes patients and insulin/SGLT2 inhibitor users at higher risk of DKA, rather than the entire 40.1 million diabetes patients in the U.S. Short-term revenue will depend on launch speed and insurance coverage, but dual regulatory approvals in the U.S. and Europe, along with the absence of competing products, strengthen Abbott’s ability to expand the Libre ecosystem through clinical differentiation rather than pricing.